<DOC>
	<DOCNO>NCT00375765</DOCNO>
	<brief_summary>Dutasteride use treatment benign prostate enlargement ( BPH ) .It inhibits conversion testosterone ( T ) potent dihydrotestosterone ( DHT ) stop prostate ( possibly prostate cancer ) growth . DHT regulate expression certain gene prostate . The pharmacodynamics DHT reduction prostate never investigate , every measurement would require prostate tissue retrieval , medically ethically unacceptable . A recently develop test able quantitatively measure gene expression prostate-borne cell , urine sediment prostate massage . By measure gene expression patient use dutasteride , become possible assess pharmacodynamics gene expression reduction , representative pharmacodynamics DHT reduction . Repeated prostate tissue sample therefore become unnecessary . This newly gain knowledge lead well understanding action dutasteride possibly help improve treatment symptomatic BPH ( Benign Prostatic Hyperplasia ) PrCa ( Prostate Cancer ) future .</brief_summary>
	<brief_title>Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer</brief_title>
	<detailed_description>A randomized , open-label , parallel-group pilot study , assess pharmacodynamic effect dihydrotestosterone regulate gene expression , longitudinally dose dependent manner , 0.5mg 3.5mg dutasteride administer orally daily , three month men symptomatic benign prostatic hyperplasia period baseline radical prostatectomy men biopsy-proven , clinically localized prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Dihydrotestosterone</mesh_term>
	<criteria>Inclusion criterion : Symptomatic BPH , : Biopsy proven , localise ( cT1 cT2 ) prostate cancer schedule radical operation Able swallow oral medication Exclusion criterion : Inability void spontaneously ( eg . dependence catheter etc . ) History ( prior ) prostate cancer Previous prostatic surgery</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dutasteride</keyword>
	<keyword>BPH</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Gene expression</keyword>
	<keyword>PSA</keyword>
</DOC>